The ELEVATE Study shows that atogepant effectively prevents episodic migraine.

Published Date: 24 Apr 2023

Atogepant (Qulipta) performed better than a placebo in the ELEVATE study for preventing episodic migraine in patients who were resistant to other treatments.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

FDA approves Blenrep for relapsed or refractory multiple myeloma

2.

More Support for Early Detection; Cancer in Men Rising; Diet Drives Colon Cancer

3.

Survey: Record Numbers of US Adults Report Depression.

4.

Climate change is expected to increase the number of suicide deaths

5.

Charles III, King of Kings, is Cancerous.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot